To assess older age and female sex, 2 of the major risk factors for potentially fatal cardiac arrhythmias or sudden cardiac death in patients prescribed psychotropics, within the context of electrocardiographic evidence of time between start of Q wave and end of T wave (QT) interval prolongation, which is an indicator of an increased risk for potentially fatal cardiac arrhythmias.
Method:
The literature on the relation between age, sex, and QT interval with respect to psychotropic drugs was reviewed.
Results:
The QT interval must be corrected (QTc) for heart rate. Because slower heart rates prolong and faster heart rates shorten the QT interval, people with faster heart rates may have a prolonged QT interval that is not apparent until the correction is performed. QTc values for apparently healthy post-pubertal people are less than 450 ms for males and less than 470 ms for females. The longer QT intervals in women may account for their increased risk of potentially fatal cardiac arrhythmias on psychotropics. QTc increases with increasing age. Assessment of QTc in older people is especially important to identify people with a longer QTc who are more likely to attain a serious QT level with drugs that prolong QTc. The age-related increase in QTc is more evident in men than women, suggesting that male sex does not afford protection against potentially fatal arrhythmias at older age.
Conclusion:
The association of increasing age and female sex with greater QT intervals indicates the need to have an increased awareness of the QTc prior to use of these psychotropics and to evaluate the QTc after initiation of therapy.
LaPointeNM AllenCurtisLHChanKAFrequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf. 2006;15:361–368.
2.
RayWAMeredithSThapaPBAntipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161–1167.
3.
HennessySBilkerWBKnaussJSCardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data. BMJ. 2002;325:1070.
4.
RayWAChungCPMurrayKTAtypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225–235.
5.
Van NoordCSturkenboomMCStrausSMNon-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death. Heart. 2011;97:215–220.
6.
Astrom-LiljaCOdebergJMEkmanEDrug-induced torsades de pointes: A review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17:587–592.
7.
ShafferDSingerSKorvickJConcomitant risk factors in reports of torsades de pointes associated with macrolide use: Review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35:197–200.
8.
RochonPAGruneirAGillSSOlder men with dementia are at greater risk than women of serious events after initiating antipsychotic therapy. J Am Geriatr Soc. 2013;61:55–61.
9.
MalikM.Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001;12:411–420.
10.
WangDCheungYBArezinaRA nonparametric approach to QT interval correction for heart rate. J Biopharm Stat. 2010;20:508–522.
11.
RabkinSWCheungXB. A nomenclature for QT—heart rate adjustment formulae: Comparison of reference and population formulae. World J Cardiol. Forthcoming 2015.
12.
BazettH.An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353–367.
13.
FridericiaL.Die sytolendauer in elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand. 1920;53:469–486. German.
14.
HodgesMSalernoDErlienD.Bazett's QT correction reviewed: Evidence that a linear QT correction for heart rate is better. J Am Coll Cardiol. 1983;1:1983.
15.
SagieALarsonMGGoldbergRJAn improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:797–801.
16.
DmitrienkoAASidesGDWintersKJElectrocardiogram reference ranges derived from a standardized clinical trial population. Drug Inf J. 2005;39:395–405.
17.
RautaharjuPMMasonJWAkiyamaT.New age- and sex-specific criteria for QT prolongation based on rate correction formulas that minimize bias at the upper normal limits. Int J Cardiol. 2014;174:535–540.
Stramba-BadialeMLocatiEHMartinelliAGender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J. 1997;18:1000–1006.
20.
KawasakiRMachadoCReinoehlJIncreased propensity of women to develop torsades de pointes during complete heart block. J Cardiovasc Electrophysiol. 1995;6:1032–1038.
21.
RautaharjuPMSurawiczBGettesLS; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: Endorsed by the International Society for Computerized Electrocardiology. Circulation. 2009;119:e241–e250.
22.
MakkarRRFrommBSSteinmanRTFemale gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590–2597.
23.
LiuXKKatchmanADriciMDGender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther. 1998;285:672–679.
24.
RautaharjuPMZhouSHWongSSex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol. 1992;8:690–695.
25.
DriciMDBurklowTRHaridasseVSex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 1996;94:1471–1474.
26.
KannankerilPRodenDMDarbarD.Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760–781.
27.
SmetanaPMalikM.Sex differences in cardiac autonomic regulation and in repolarisation electrocardiography. Pflugers Arch. 2013;465:699–717.
28.
HreicheRMorissettePTurgeonJ.Drug-induced long QT syndrome in women: Review of current evidence and remaining gaps. Gend Med. 2008;5:124–135.
GirardinFRGex-FabryMBerneyPDrug-induced long QT in adult psychiatric inpatients: The 5-year cross-sectional ECG Screening Outcome in Psychiatry study. Am J Psychiatry. 2013;170:1468–1476.
31.
IribarrenCRoundADPengJAValidation of a population-based method to assess drug-induced alterations in the QT interval: A self-controlled crossover study. Pharmacoepidemiol Drug Saf. 2013;22:1222–1232.
32.
LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
33.
HarriganEPMiceliJJAnzianoRA randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62–69.
34.
CohenHLoewenthalUMatarMAssociation of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry. 2001;179:167–171.
35.
TisdaleJEKovacsRMiDAccuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol. Pharmacother J Hum Pharmacol Drug Ther. 2007;27:175–182.
36.
CammAJKarayalONMeltzerHZiprasidone and the corrected QT interval: A comprehensive summary of clinical data. CNS Drugs. 2012;26:351–365.
37.
RabkinSW. Aging effects on QT interval: Implications for cardiac safety of antipsychotic drugs. J Geriatr Cardiol. 2014;11:20–25.
38.
StrausSMBleuminkGSDielemanJPAntipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164:1293–1297.
39.
AgelinkMWMajewskiTWurthmannCEffects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol. 2001;21:8–13.
40.
MorissettePHreicheRMalletLOlanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol. 2007;21:735–741.
41.
SuzukiYSugaiTFukuiNSex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. Hum Psychopharmacol. 2013;28:215–219.
42.
HasnainMViewegWVHowlandRHQuetiapine and the need for a thorough QT/QTc study. J Clin Psychopharmacol. 2014;34:3–6.
43.
HoughDWNatarajanJVandeboschAEvaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: A randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:25–34.
44.
PotkinSGPreskornSHochfeldMA thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33:3–10.
45.
SuzukiYSugaiTFukuiNChanges in QT interval after switching to quetiapine in Japanese patients with schizophrenia. Hum Psychopharmacol. 2013;28:94–96.
46.
LevyWORobichaux-KeeneNRNunezC.No significant QTc interval changes with high-dose ziprasidone: A case series. J Psychiatr Pract. 2004;10:227–232.
47.
HeinrichTWBibloLASchneiderJ.Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47:264–268.
48.
GrecoKETuneLEBrownFWA retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. J Clin Psychiatry. 2005;66:928–929.
49.
NythALGottfriesCGLybyKA controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86:138–145.
50.
RasmussenSLOveroKFTanghojP.Cardiac safety of citalopram: Prospective trials and retrospective analyses. J Clin Psychopharmacol. 1999;19:407–415.
51.
Van HaelstIMvan KleiWADoodemanHJQT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: A cross-sectional study. J Clin Psychiatry. 2014;75:15–21.
52.
PorsteinssonAPDryeLTPollockBG; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA. 2014;311:682–691.
53.
DryeLTSpraggDDevanandDP; CitAD Research Group. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS ONE. 2014;9:e98426. doi: 10.1371/journal.pone.0098426. eCollection 2014.
54.
ShahRR. The significance of QT interval in drug development. Br J Clin Pharmacol. 2002;54:188–202.
55.
DeshmukhAUlvelingKAllaVProlonged QTc interval and torsades de pointes induced by citalopram. Texas Hear Inst J. 2012;39:68–70.
56.
FayssoilAIssiJGuerbaaMTorsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris). 2011;60:165–168.
57.
KanjanauthaiSKanluenTChareonthaitaweeP.Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol. 2008;131:e33–e34.
58.
US Department of Health and Human Services Food and Drug Administration (FDA). FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Silver Spring (MD): FDA;2012 Mar 28 [updated 2013 Feb 15; cited 2014 Sep 15]. Available from: http//www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
59.
BlaschkeDParwaniASHuemerMTorsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry. 2007;40:294–295.
TsengPTLeeYLinYELow-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: A case report and literature review. Gen Hosp Psychiatry. 2012;34:210.e13–210.e15.
62.
LetsasKKorantzopoulosPPappasLQT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006;109:116–117.
63.
HowellCWilsonADWaringWS. Cardiovascular toxicity due to venlafaxine poisoning in adults: A review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64:192–197.
64.
IsbisterGK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol. 2009;67:572–576.
